Poster presentations 2017
P1. Need for pre-exposition prophylaxis to HIV-1 in Sweden
Bo Hejdeman
P5. Targeting HIV testing service yields early HIV diagnosis among men having sex with men (MSM)
Pia Kivelä
P7. Safety and efficacy of the GnRH analouge buserelin in HIV treatment; a phase IIa study
Ola Winqvist
P8. Potency of a novel translocation defective reverse transcriptase inhibitor, EFdA in comparison to NNRTIs on diverse HIV-1 subtypes
Duncan T. Njenda
P9. Antiretroviral potency of second generation INSTIs in different HIV-1 subtypes and major accessory mutations in treatment naïve individuals
Shambhu G Aralaguppe
P12. Low Risk Of Virologic Failure In Rilpivirine Treated Patients In The Swedish InfcareHIV Cohort
Piotr Nowak
P13. Dolutegravir in pregnancy – effects on HIV-positive women and their infants
Riikka Bornhede
P14. Cervicovaginal inflammation is strongly modulated by cyclic changes in sex hormones and amplified by the microbiome
Frideborg Bradley*, Kenzie Birse*, Klara Hasselrot, Laura Romas, Andrea Introini, Hugo Wefer, Maike Seifert, Lars Engstrand, Annelie Tjernlund, Kristina Broliden, Adam Burgener
*Contributed equally to this work
P15. Highly HIV-exposed HIV uninfected Kenyan female sex workers display a thick ectocervical epithelium
Maria Röhl, Julie Lajoie
P16. Hormonal contraceptive use affects HIV susceptibility: mechanisms revealed by image analysis
Gabriella Edfeldt
P17. HIV-infected women have high numbers of CD103-CD8+ T cells residing close to the basal membrane of the ectocervical epithelium
Annelie Tjernlund
P18. CSF levels of the glial marker YKL-40 are strongly associated with neuronal injury in HIV
Linn Hermansson
P19. Effect of antiretroviral treatment on blood-brain barrier integrity in neuroasymptomatic HIV-1-infected patients
Birgitta Anesten
P21. Characteristic pattern of soluble biomarkers in HIV-1 elite controllers
Maike Sperk
P22. MiDRMpol: A simplified, cloud based algorithm to identify minor HIV-1 drug resistance mutations
Anoop T. Ambikan
P23. Increasing prevalence of transmitted drug resistance mutations in migrants from Sub Saharan Africa diagnosed with HIV-1 in Sweden
Emmi Andersson
P24. Prevalence of ARV resistance in Ugandan children, at treatment start and after six months of treatment
Sandra Soeria-Atmadja
P26. Increased binding to ALIX but no effect on viral growth for HIV-1 subtype C gag with PYKE insertion
Robert van Domselaar
P27. Phenotypic properties of transmitted/founder (TF) virus from recently diagnosed infants from India
Ashokkumar Manickam
P28. HIV-1 Vpu and Nef proteins interfere with MR1 surface expression
Jean-Baptiste Gorin
P30. Three dimensional Slipdisc aimed at HIV viral load detection
Indradumna Banerjee
P33. Chronic hepatitis C virus infection irreversibly impacts human NK cell repertoire diversity
Benedikt Strunz, Julia Hengst
P34. Insufficient HCV testing in an OAT clinic in Stockholm calls for changes in testing routines
Martin Kåberg
P35. Nonreversible imprint on the soluble and cellular immune system by chronic hepatitis C
Julia Hengst
P36. Phylogenetic reconstruction of hepatitis C virus transmission in Southern Sweden (2007-2015)
Malik Sallam
P37. Sofosbuvir and Velpatasvir for HCV in People with Recent Injecting Drug Use
Olav Dalgard
P38. Quantification of HCV-RNA and Determination Anti-HCV from Dried Blood Spots Sent by Regular Mail: A pilot study
Bastian Neesgaard
P40. Medication utilization in chronic hepatitis c patients: a nationwied register based study
Büsch K
P41. Prevalence of Hepatitis B virus and associated risk factors among Malayali tribes, Yelagiri Hills, India
Delfin Lovelina Francis
P42. Outcomes of severe acute viral hepatitis B in Latvia
Jekaterina Kucina
P43. A combined therapeutic vaccine for chronic HBV/HDV infections raises broadly crossreactive and neutralizing antibodies and genotype specific T cells
Panagiota Maravelia